Drug Trial Radar · NCT02783729
Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,006
Actual
Start
May 31, 2016
Primary completion
Jan 30, 2018
Study completion Jan 30, 2018
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- May 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to demonstrate, using polysomnography, that lemborexant 10 milligrams (mg) and 5 mg is superior to placebo on objective sleep onset as assessed by latency to persistent to sleep (LPS) after the last 2 nights of 1 month of treatment in participants 55 years and older with insomnia disorder.
Conditions
- Insomnia
Interventions
LemborexantDrug
Lemborexant 5 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
LemborexantDrug
Lemborexant 10 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Lemborexant-matched placeboDrug
Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Zolpidem tartrateDrug
Zolpidem tartrate extended release 6.25 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Zolpidem-matched placeboDrug
Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Latency to Persistent Sleep (LPS) of Lemborexant 10 mg and Lemborexant 5 mg Compared to Placebo on Days 29/30Time frame: Baseline, Days 29/30
Locations
102 sites in 7 countries. Site status is shown where the registry gives one.
Jasper Summit Research LLC
Jasper, Alabama
PACT
Glendale, Arizona
Preferred Research Partners
Little Rock, Arkansas
Site not named
Carlsbad, California
Southern California Research
Fountain Valley, California
Pacific Sleep Medicine Services
Oceanside, California
Research Center of Southern California
Oceanside, California
Orange County Neuropsychiatric Research Center, LLC
Orange, California
SDS Clinical Trials, Inc.
Orange, California
Artemis Institute For Clinical Research LLC
San Diego, California
Pacific Research Network Inc
San Diego, California
Artemis Institute For Clinical Research
San Marcos, California
Santa Monica Clinical Trials
Santa Monica, California
Empire Clinical Research
Upland, California
PAB Clinical Research
Brandon, Florida
Saint Francis Sleep Allergy and Lung Institute
Clearwater, Florida
Fleming Island Center For Clinical Research
Fleming Island, Florida
Sarkis Clinical Trials
Gainesville, Florida
MD Clinical
Hallandale, Florida
QPS MRA
Hollywood, Florida
Quest Pharmaceutical Services-Miami Research Associates, LLC (QPS MRA)
Miami, Florida
Research Centers of America
Oakland Park, Florida
Compass Research LLC
Orlando, Florida
NeuroMedical Research Institute
Panama City, Florida
Clinical Research Group of St Petersburg Inc
St. Petersburg, Florida
NeuroTrials Research Inc.
Atlanta, Georgia
SleepCare Research Institute Inc
Stockbridge, Georgia
Northwestern University
Chicago, Illinois
Chicago Research Center Inc
Chicago, Illinois
Helene A Emsellem MD PC
Chevy Chase, Maryland
Sleep Disorders Center of the Mid-Atlantic
Glen Burnie, Maryland
Neurocare Inc
Newton, Massachusetts
University of Michigan
Ann Arbor, Michigan
Henry Ford Hospital
Novi, Michigan
Clinical Neurophysiology Services
Sterling Heights, Michigan
St. Louis Clinical Trials
St Louis, Missouri
Clayton Sleep Institute
St Louis, Missouri
Clinical Research Center of Nevada
Las Vegas, Nevada
Hassman Research Institute
Berlin, New Jersey
CLINiLABS, Inc.
Eatontown, New Jersey
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.